Cargando…
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Molecular targeted drugs are clinically effective anti-cancer therapies. However, tumours treated with single agents usually develop resistance. Here we use colorectal cancer (CRC) as a model to study how the acquisition of resistance to EGFR-targeted therapies can be restrained. Pathway-oriented ge...
Autores principales: | Misale, Sandra, Bozic, Ivana, Tong, Jingshan, Peraza-Penton, Ashley, Lallo, Alice, Baldi, Federica, Lin, Kevin H., Truini, Mauro, Trusolino, Livio, Bertotti, Andrea, Di Nicolantonio, Federica, Nowak, Martin A., Zhang, Lin, Wood, Kris C., Bardelli, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4595628/ https://www.ncbi.nlm.nih.gov/pubmed/26392303 http://dx.doi.org/10.1038/ncomms9305 |
Ejemplares similares
-
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
por: Lorenzato, Annalisa, et al.
Publicado: (2020) -
Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2018) -
Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways
por: Invrea, Federica, et al.
Publicado: (2021) -
β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth
por: Bertotti, Andrea, et al.
Publicado: (2006) -
Evolving neoantigen profiles in colorectal cancers with DNA repair defects
por: Rospo, Giuseppe, et al.
Publicado: (2019)